Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
← catalyst calendarNCT07157514 · readout ≤ 924 d
Sponsored by Actinium Pharmaceuticals (industry) · ATNM — their whole pipeline →.
Phase
Phase 2/3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
306estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2026 | estimated | When the study began enrolling |
| Primary completion | Feb 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2034 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Leukemia
- Myeloid Leukemia
- Acute Myelogenous Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia, in Relapse
- Myelogenous Leukemia
- Myelogenous Leukemia, Acute
- Myelogenous Leukemia in Relapse
- Transplant-Related Disorder
- Allogeneic Disease
- Refractory AML
Interventions
- Drug: 131I-apamistamab
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Radiation: Total Body Irradiation (TBI)
- Biological: Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS) -Phase 3
measured Up to 5 years post-randomization
Complete Remission (CR) at Day 28 Post-HSCT - Phase 2
measured Day 28 post-HSCT
Incidence of Grade ≥4 Non-Hematologic Toxicity
measured Up to 6 months post-HSCT
Permalink · ATNM's whole pipeline · Catalyst calendar · Every registered study · What changed